The purpose of the Center for Medicinal Cannabis Research is to coordinate rigorous scientific studies to assess the safety and efficacy of cannabis and cannabis compounds for treating medical conditions.
2017 National Academies Report
CMCR Legislative Report
2000 IOM Report
1999 IOM Report
NBC News, January 3, 2019
It used to be the stuff of stoner comedies and “Just Say No” campaigns. Today, marijuana is becoming mainstream as voters across the country approve ballot questions for legalization or medical use.
In response, state governments are testing ways to ensure that the integration of this once-illicit substance into everyday life doesn’t create new public health risks. These efforts are sparking a difficult question: At what point is someone too high to get behind the wheel?
The answer is complicated. Brain scientists and pharmacologists don’t know how to measure if and to what extent marijuana causes impairment.
Read the rest of the story here
Alex Hannaford, BBC, November 22, 2018
There’s vape oil, pain-relief cream, patches, sweets (gummy bears, sour snakes, rainbow bites – take your pick), capsules and compounds.
Cannabidiol, or CBD as it’s better known – a naturally occurring extract of the cannabis sativa plant – is now so ubiquitous in the US, you’d be forgiven for thinking there are few places it's not available and few ailments it cannot treat.
Users say they take it for everything from muscle aches and anxiety to arthritis, epilepsy and Post Traumatic Stress Disorder.
And let’s not forget Fido. There’s CBD oil for him too – with added bacon flavour.
Gabrielle Johnston, MPH, UC San Diego Health, October 30, 2018
It seems like everywhere you turn cannabis or cannabis derivatives can be found. From ingredients in coffee and smoothies to being marketed as medicine, a cannabis craze seems to be sweeping the country. Since 2000, UC San Diego School of Medicine’s Center for Medicinal Cannabis Research and its affiliated researchers have been studying marijuana and its derivatives, their effects on mind and body and their therapeutic potential.
We asked experts to cut through the hyperbole and haze to answer some burning questions.
Gary Robbins, San Diego Union Tribune, October 10, 2018
Emerald Health Pharmaceuticals of San Diego has begun using a marijuana-derived therapy to experimentally treat small numbers of people who suffer from multiple sclerosis and scleroderma, a pair of autoimmune diseases.
The small, phase 1 safety trial involves CBD, a compound found in marijuana. CBD has caught the attention of researchers because it does not get people high, and it has anti-inflammatory properties.
The trial is meant to determine whether the therapy is safe, what dose should be used, and if there are any side effects or related problems.
Emerald Health says it also is developing another non-psychoactive compound found in marijuana — CBG — for possible use in treating patients with Huntington’s disease and Parkinson’s disease.
UC San Diego is preparing to use CBD in a clinical trial that’s meant to people who suffer from epilepsy.
Igor Grant, MD
Introduction/Overview
CMCR Symposium, June 2018
Daniele Piomelli, MD, PhD, PharmD
The health impact of cannabis
CMCR Symposium, June 2018
Ziva Cooper, PhD
Therapeutic potential of cannabis for pain alone and as an adjunct to opioids
CMCR Symposium, June 2018
Iain McGregor, PhD
Medicinal cannabis research down under: Introducing the Lambert Initiative for Cannabinoid Therapeutics
CMCR Symposium, June 2018
Thomas Marcotte, PhD
Cannabis and public safety: The challenge of cannabis-impaired driving
CMCR Symposium, June 2018
Alan Budney, PhD
Medicinal cannabis / legalization and the development of cannabis use problems
CMCR Symposium, June 2018
Ryan Vandrey, PhD
What's in real-world cannabis?
CMCR Symposium, June 2018